Amended Annual Report (10-k/a)
March 25 2016 - 6:14AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K
Amendment
No. 3
[X]
|
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For
the fiscal year ended August 31, 2015
[ ]
|
TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Commission
file number: 000-52445
PETLIFE
PHARMACEUTICALS, INC.
(FORMERLY
CLEAR TV VENTURES, INC.)
(Name
of registrant as specified in its charter)
Nevada
|
|
33-1133537
|
(State
or other jurisdiction of
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
Identification
No.)
|
|
|
|
433
N. Camden Dr.
Beverly
Hills, CA
|
|
90210
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(310)
279-5152
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
None
Securities
registered pursuant to Section 12(g) of the Act:
Common
Stock, $0.001 par value
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes
[ ] No [X]
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.
Yes [ ] No [X]
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). Yes [X] No[ ]
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See definition of “accelerated filer”, “large accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer [ ]
|
|
Accelerated
filer [ ]
|
|
Non-accelerated
filer [ ]
|
|
Smaller
reporting company [X]
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]
The
aggregate market value of the common stock of the registrant held by non-affiliates as of November 28, 2014 the last business
day of the registrant’s most recently completed first fiscal quarter based on the closing sale prices of the registrant’s
common stock on that date as reported on the OTCQB maintained by OTC Markets Group, Inc. was $15,338,480. For purposes of this
computation, all officers, directors, and 5 percent beneficial owners of the registrant are deemed to be affiliates. Such determination
should not be deemed an admission that such directors, officers, or 5 percent beneficial owners are, in fact, affiliates of the
registrant.
The
number of shares of the registrant’s common stock outstanding as of December 24, 2015 was 38,115,356 shares.
This
Amendment No. 3 to the Form 10-K for Petlife Pharmaceuticals, Inc. for the fiscal year ended August 31, 2015 is only filed to
include the required officer certifications required to be filed as Exhibits by in Item 601(b)(31) and (32) or Regulation S-K
which were not filed as exhibits to Amendment No. 2.
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual
Report on Form 10-K for the fiscal year ended August 31, 2015 to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Petlife Pharmaceuticals, Inc.
|
March
24, 2016
|
|
|
|
By:
|
/s/
Arthur G. Mikaelian
|
|
|
Arthur
G. Mikaelian
|
|
|
Chief
Executive Officer, Director
|
|
|
|
|
|
/s/
Arthur G. Mikaelian
|
|
|
Chief
Financial & Principal Accounting Officer
|
EXHIBIT
INDEX
Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
2.1
|
|
Agreement
and Plan of Merger dated as of June 26, 2014 between Eco Ventures Group, Inc. and PetLife Pharmaceuticals, Inc. (i)
|
|
|
|
3.2
|
|
Bylaws
(ii)
|
|
|
|
10.1
|
|
Reorganization
Agreement dated as of April 28, 2014 by and between Eco Ventures Group, Inc. and PetLife Corporation (i)
|
|
|
|
10.2
|
|
Patent
License Agreement dated as of August 1, 2014 between Arthur Grant Mikaelian and Petlife Pharmaceuticals, Inc. (i)
|
|
|
|
10.3
|
|
Manufacturing
Agreement dated as of May 8, 2014 between Petlife Corporation and Samson Pharmaceuticals, Inc. (i)
|
|
|
|
31.1
|
|
Certification
Pursuant to Rule 13A-14 or 15D-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002 signed by the Principal Executive Officer
|
|
|
|
31.2
|
|
Certification
Pursuant to Rule 13A-14 or 15D-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002 signed by the Principal Financial Officer
|
|
|
|
32.1
|
|
Certification
Required by 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 signed by Principal
Executive Officer and Chief Financial Officer
|
|
|
|
101
|
|
Interactive
data files (iii)
|
(i)
Incorporated herein by reference to the Company’s Periodic Report on Form 8-K filed on April 8, 2014.
(ii)
Incorporated herein by reference to the original filing of this Annual Report on Form 10-K.
(iii)
Previously filed.
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Jul 2023 to Jul 2024